Tiziana Life Sciences plc TLSA 深 沪
已收盘 09-04 16:00:00 美东时间
1.02
+0.046
+4.67%
华盛通- 最 高1.06
- 今 开0.972
- 成交量 57.39万股
- 最 低 0.9507
- 昨 收 0.9745
- 总市值 1.30亿
- 52周最高 2.35
- 市盈率 静 --
- 换手率 0.45%
- 52周最低 0.8663
- 委 比 60.59%
- 总股本 1.27亿
- 历史最高 12.15
- 量 比 1.14
- 振 幅 11.22%
- 历史最低 0.41
- 每 手 1
- 风险率 0.31%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 大行齐上调AI应用股目标价！Adobe、CRWD等获看好，慧与科技绩后现多空分歧
今日重点评级关注：BTIG：维持Climb Bio"买入"评级，目标价从20美元升至32美元；巴克莱：维持Alpha Tau Medical"超配"评级，目标价从17美元升至30美元
09-04 12:30
BTIG Initiates Coverage On Tiziana Life Sciences with Buy Rating, Announces Price Target of $7
BTIG analyst Thomas Shrader initiates coverage on Tiziana Life Sciences (NASDAQ:TLSA) with a Buy rating and announces Price Target of $7.
09-03 18:08
Tiziana Life Sciences To Present Poster, Titled Phase 2a Trial Of Intranasal Foralumab – BANYAN, A Healey ALS MyMatch Trial, At ALS Nexus 2026
Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that a poster, titled "Phase 2a T...
08-24 19:04
Tiziana Life Sciences Announces Poster Presentation on Phase 2a BANYAN Clinical Trial of Intranasal Foralumab at ALS Nexus 2026
Tiziana Life Sciences announced the presentation of a Phase 2a trial for intranasal foralumab, a fully human anti-CD3 monoclonal antibody, in ALS patients at ALS Nexus 2026. The BANYAN trial, part of the Healey ALS MyMatch program, aims to assess safety, immune modulation biomarkers, and early clinical effects. Foralumab targets the regulatory T cell (Treg) pathway, which is critical in ALS pathogenesis, by expanding and activating Tregs to suppr...
08-24 11:00
Tiziana Life Sciences Announces Quantitative PET Imaging Results From Third Patient With Multiple System Atrophy In Its Phase 2 Clinical Trial Treated With Intranasal Foralumab To Complete Dosing; Scans Demonstrated Reductions In Inflammatory Activity
Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana"), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces quantitative PET imaging results from the third patient with Multiple System Atrophy (MSA) in the Phase 2 clinica...
07-31 19:08
Tiziana Reports Reduction in Brain Inflammation in Third Multiple System Atrophy Patient Treated with Intranasal Foralumab
Tiziana Life Sciences reports positive results from the third MSA patient in its Phase 2 trial, showing a 34% reduction in SUV and 26% in SUVR in brain regions affected by MSA after treatment with intranasal foralumab. These findings align with previous patients, supporting the therapy's potential to reduce neuroinflammation. Tiziana plans to continue evaluating the treatment in additional patients.
07-31 11:00
Tiziana Life Sciences shares are trading higher after the company announced its executive chairman bought 42,357 shares.
Tiziana Life Sciences shares are trading higher after the company announced its executive chairman bought 42,357 shares.
07-22 21:05
Tiziana Life Sciences Announces Purchase of Shares by Executive Chairman
Tiziana Life Sciences创始人Gabriele Cerrone增持公司股份至34.93%。公司核心产品Foralumab，一种全人源抗CD3单克隆抗体，通过鼻腔给药，已在14例非活动性继发进展型多发性硬化症患者中显示出疗效。目前正在进行两项临床试验，包括一项IIa期随机双盲安慰剂对照试验。Foralumab是唯一进入临床开发的全人源抗CD3单抗，具有治疗神经炎症和神经退行性疾病的新潜力。
07-22 11:00
Tiziana Announces Last Patient In Ongoing Phase 2a Clinical Trial Receives First Dose Of Intranasal Foralumab For Treatment Of Non-Active Secondary Progressive Multiple Sclerosis; Topline Data Expected In Late Q3/Early Q4 Of 2026
Top line data readout expected in late Q3/early Q4 INFORM-MS trial is a randomized, double-blind, placebo-controlled Phase 2a trial using Intranasal Foralumab in patients with Non-Active Secondary Progressive Multiple Sclerosis BOSTON, June 25, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. ...
06-25 19:03
Tiziana Announces Last Patient Successfully Dosed in its Phase 2 INFORM-MS Trial
Tiziana Life Sciences announces the completion of first dosing in its Phase 2a INFORM-MS trial for intranasal foralumab in non-active secondary progressive multiple sclerosis (na-SPMS). Topline data expected late Q3/early Q4 2026. The randomized, double-blind, placebo-controlled trial evaluates safety, tolerability, and efficacy in up to 48 patients. Primary endpoint is change in microglial activation via PET scans. The trial is conducted at lead...
06-25 11:00
